Sun Pharma launches Tedizolid Phosphate tablets in India

23 Aug 2024 Evaluate

Sun Pharmaceutical Industries has launched Tedizolid Phosphate tablets 200 mg in India under the brand name ‘STARIZO’. STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India.

STARIZO (Tedizolid Phosphate) is a once-a-day oral treatment for six days compared to the current standard of care which has to be given twice daily for 10-14 days. STARIZO (Tedizolid Phosphate) has demonstrated activity against gram-positive organisms, including MRSA. STARIZO (Tedizolid) provides the advantage of reduced frequency and duration of drug administration. STARIZO (Tedizolid Phosphate) requires no dose adjustment in the elderly, patients with hepatic or renal impairment and patients on haemodialysis. Tedizolid Phosphate is sold in India under a licensing agreement with Merck Sharp & Dohme Singapore Trading PTE.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1854.15 7.20 (0.39%)
07-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1854.15
Dr. Reddys Lab 1350.75
Cipla 1497.80
Lupin 2357.65
Zydus Lifesciences 1001.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.